title: Pharmacological properties of YM264, a potent and orally active antagonist of platelet-activating factor.
abstract: The anti-platelet-activating factor effect of YM264 was examined in a variety of in vitro and in vivo test systems. YM264 inhibited [3H] platelet-activating factor binding to rabbit platelet membranes with a pKi value of 8.85. YM264 inhibited the platelet-activating factor-induced human, rabbit and guinea-pig platelet aggregation with pA2 values of 8.68, 8.33 and 8.14, respectively. However, at 10(-4) M the compound did not affect rabbit and human platelet aggregation induced by ADP, collagen arachidonic acid and epinephrine. YM264 reversed a platelet-activating factor-induced hypotension is anesthetized rats with an ED50 value of 0.005 mg/kg, i.v. Administered orally, YM264 inhibited platelet-activating factor-induced death in mice, hemoconcentration in rats and increase in vascular permeability in guinea-pigs with ED50 values of 0.19, 0.30 and 0.49 mg/kg, p.o., respectively. YM264, at 1 and 3 mg/kg, p.o., showed a significant anti-platelet-activating factor effect in a rat hemoconcentration model up to 6 hr after treatment. Moreover, in ex vivo experiments in guinea-pigs, YM264, at the doses of 0.3 to 3 mg/kg, p.o., shifted the dose-response curves of platelet-activating factor-induced platelet aggregation to the right in a parallel manner. These results indicate that YM264 is a selective, potent and orally active platelet-activating factor antagonist.
authors.affiliation: Central Research Laboratories, Yamanouchi Pharmaceutical Co., Ltd., Ibaraki, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Yamada
authors.forename: K
authors.initials: K
authors.lastname: Tomioka
authors.forename: M
authors.initials: M
authors.lastname: Saito
authors.forename: M
authors.initials: M
authors.lastname: Horie
authors.forename: T
authors.initials: T
authors.lastname: Mase
authors.forename: H
authors.initials: H
authors.lastname: Hara
authors.forename: H
authors.initials: H
authors.lastname: Nagaoka
mesh_terms: D000818:Animals; D001792:Blood Platelets / Q000378:metabolism / Q000648:ultrastructure; D001794:Blood Pressure / Q000187:drug effects; D002199:Capillary Permeability / Q000187:drug effects; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D006168:Guinea Pigs; D006400:Hematocrit; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008813:Mice, Inbred ICR; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains; D013844:Thiazoles / Q000494:pharmacology*; D053778:Thiazolidines
chemical_list: D010879:Piperazines; D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; D013844:Thiazoles; D053778:Thiazolidines; C068679:YM 264